• Revelation Biosciences Inc REVB announced topline data for its Phase 1b CLEAR study to evaluate the effect of intranasal REVTx-99b on nasal challenge allergen in participants with allergic rhinitis to rye grass pollen.
  • The study met the primary endpoint evaluating the effects of REVTx-99b versus placebo on safety and tolerability. 
  • Exploratory endpoints for efficacy were not met, including no reduction in allergy symptoms and increase in peak nasal inspiratory flow versus placebo. 
  • Revelation management plans to evaluate the future development of this and other ongoing programs.
  • REVTx-99b is a proprietary intranasal formulation in development for managing allergic rhinitis symptoms, including chronic nasal congestion. 
  • Phase 2b viral challenge study data announced in March showed that REVTx-99a did not meet its primary endpoint, the area under the curve of viral load by quantitative RT-PCR from nasopharyngeal swabs.
  • Price Action: REVB shares are up 78.9% at $1.15 during the premarket session on the last check Monday.


Source link